N/A N=14,144 COVID-19 Health Messaging to Underserved Communities
Coronavirus
Primary: Incidence Rate for Knowledge Gaps: Control vs. Any Intervention — 0.085; 0.065 proportion of knowledge gaps
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=131 Noninvasive Hemoglobin Testing, Prospective Blood Donors
Healthy · Anemia
Primary: Rad-67 Sensitivity — 44 percentage of sensitivity
N/A N=225 Clinical Investigation of the Next-Generation Intraocular Lenses
Cataract
Primary: Distance Corrected Intermediate Visual Acuity — 0.098; 0.219; 0.147 LogMAR
N/A N=95 Cognitive Dysfunction In Parkinson's
Parkinson's
Primary: Differences in Error Rates on the NBack Task Between Real and Sham Stimulation Trials — -0.79; -0.1 incorrect responses
N/A N=20,460 Covid-19 Messaging to Underserved Communities - 2nd Experiment
Covid19
Primary: Incidence Rate for Knowledge Gaps: Control vs. Any Intervention — 0.214; 0.241 proportion of knowledge gaps
N/A N=135 Reducing Disparities in Medication Adherence in SLE
Systemic Lupus Erythematosus
Primary: Feasibility as Measured by Number of Participants With EMR (Electronic Medical Record) Documentation of Adherence — 116 Participants
Phase 4 N=46 Neuroendocrine Dysfunction in Traumatic Brain Injury: Effects of Testosterone Therapy
Endocrine Dysfunction · Trauma · Brain Injury
Primary: Restricted Functional Independence Measure (FIM) — 34; 16; 21; 52 units on a scale — p=0.9540
Phase 3 N=260 Effectiveness Novel Tissue Sealant, Prevention Prolonged Air Leak (PAL) After Lung Resection
Prolonged Air Leak · Lung Resection
Primary: Number of Participants With Prolonged Air Leak (PAL) — 33; 24 Participants — p=0.171
Phase 1 N=45 Evaluating the Safety and Immunogenicity of an HIV Vaccine (gp145 C.6980) in Healthy, HIV-Uninfected Adults in the United States
HIV Infections
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness — 9; 4; 4; 14 Participants
Phase 2 N=28 TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast Cancer
Estrogen Receptor Positive Breast Cancer
Primary: Ki67 Expression — 15; 10 Percentage of cells with Ki67 expression — p==0.0023
Phase 2 N=64 Sulforaphane to Reduce Symptoms of Schizophrenia
Schizophrenia · Schizoaffective Disorder
Primary: Change in Positive and Negative Syndrome Scale (PANSS) Score From the Start to the End of the Double-blind Treatment Phase — 81.0; 81.5; 81.7; 79.7 score on a scale
Phase 1 N=10 Pilot Study: Safety of Chlorhexidine (CHG) Baths in Patients Less Than 2 Months of Age
Chlorhexidine Allergy · Infection · Rash
Primary: Percentage of Study Participants With Skin Reactions Less Than 10% — 0; 2 Participants
N/A N=47 Feasibility of a Multi-Level School Intervention for LGBTQ Youth
Sexual Minority Stress Experiences Among LGBTQ Youth
Primary: Sexual Minority Adolescent Stress Inventory (SMASI) — 8.44; 7.22; 7.59; 8.29 score on a scale
Phase 2 N=109 Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Focal Segmental Glomerulosclerosis
Primary: Percent Change in Urine Protein/Creatinine (Up/C) — -44.8; -18.5; -47.4; -33.1 percent change
N/A N=15,786 Using a Teachable Moment Communication Process to Improve Outcomes of Quitline Referrals
Smoking · Tobacco Dependence
Primary: Number of Patients Contacted for Quitline Enrollment — 273; 59 Participants — p=.05